Welcome to our dedicated page for Pharmala Biotech news (Ticker: MDXXF), a resource for investors and traders seeking the latest updates and insights on Pharmala Biotech stock.
PharmAla Biotech Holdings Inc. (OTCQB: MDXXF) is a biotechnology company in the healthcare sector that focuses on the research, development, and manufacturing of MDXX class molecules, including MDMA. Its news flow centers on clinical-grade MDMA supply agreements, progress in its ALA-002 development program, and updates on its role in MDMA-assisted therapy research.
Company announcements frequently highlight contracts to supply LaNeo MDMA for investigator-sponsored and other clinical trials at leading institutions. Recent releases describe shipments or supply agreements involving the University of Washington, Yale University, Johns Hopkins University, Mt. Sinai Health System, Østfold Hospital Trust in Norway, and the STRONG STAR Consortium led by UT Health San Antonio and Emory University. These updates often explain how LaNeo MDMA will be used in studies of conditions such as PTSD and personality disorders.
PharmAla’s news also covers developments in its pipeline, particularly ALA-002, a patented, novel, non-racemic MDMA formulation. The company has reported the issuance of a US patent for ALA-002 and has announced manufacturing arrangements for ALA-002 drug substance through its subsidiary PharmAla Biotech Australia and a UK-based CDMO.
Operational and regulatory milestones are another recurring theme, including new distribution and logistics partnerships, the launch of a clinical trial tool that provides researchers with access to CMC data and the Investigator’s Brochure, and corporate governance items such as option grants and advisory agreements. Investors and researchers following MDXX class drug development, MDMA-assisted therapy, and clinical trial supply can use this news page to review PharmAla’s disclosed contracts, research collaborations, and corporate updates over time.
PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTC:MDXXF) has launched a new MDMA Clinical Trial Tool for researchers. This tool provides direct access to Chemistry, Manufacturing and Control (CMC) data and the company's investigator's brochure to qualified researchers. The initiative comes in response to a surge in requests for MDMA research materials following the FDA's decision on Lykos' New Drug Application for MDMA.
The tool, available at pharmala.ca/clinical-trials, aims to streamline the process for researchers applying for trials with MDMA and boost PharmAla's sales pipeline for clinical trials using LaNeo MDMA. Additionally, PharmAla announced the appointment of William Avery, CPA, CA, as the new Chief Financial Officer, effective October 1st, replacing outgoing CFO Carmelo Marelli.
PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTC:MDXXF) has responded to the USFDA's decision to request a third confirmatory Phase 3 trial for MDMA-assisted therapy in treating PTSD. While disappointed, PharmAla's CEO Nicholas Kadysh emphasized the company's US operations and commitment to ongoing research. PharmAla currently supplies LaNeo™ MDMA for patient treatments in Canada and Australia under special access programs.
Additionally, PharmAla announced the USPTO issuance of patent No. 12,053,452 for ALA-002, its novel non-racemic mixture of MDMA enantiomers. This patent is seen as a valuable asset in PharmAla's R&D program, addressing safety concerns associated with racemic MDMA and potentially positioning ALA-002 favorably for regulatory approval.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.